Overview

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
All
Summary
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with recurrent or progressive malignant glioma. ANG1005 will be given by IV infusion once every 21 days (1 treatment cycle). Each patient will participate in only 1 dose group and will receive up to 6 cycles of treatment provided there is no evidence of tumor progression, there is recovery to ≤Grade 1 or baseline nonhematologic, ANG1005-related toxicity (except alopecia), the absolute neutrophil count is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Angiochem Inc
Criteria
Inclusion Criteria:

1. Written informed consent

2. Histologically confirmed malignant glioma

3. Radiologically confirmed progression of malignant glioma

4. Patients must, in the opinion of the investigator, be ineligible for current standard
of care treatment

5. No evidence of acute intracranial/intratumoral hemorrhage

6. Male and female patients

7. Age ≥18 years

8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

9. An expected survival of at least 3 months

10. Measurable disease according to Macdonald response criteria

11. Male and female subjects who are not surgically sterile or post-menopausal must agree
to use reliable methods of birth control for the duration of the study and for 90 days
after the last dose of study drug administration; male partners of female subjects
should use condoms for the duration of the study, and for 90 days after the last dose
of study drug administration

Exclusion Criteria:

1. Chemotherapy, radiotherapy (except palliative radiation delivered to <20% of bone
marrow), or investigational agents within 4 weeks before the first dose of study drug.
Biologic therapy (such as 13-cis-retinoic acid, thalidomide, tamoxifen, celebrex,
erlotinib, imatinib, vorinostat, and lapatinib) and immunotherapy (such as interferon
a or b, cdx-110 (EGFR vIII vaccine), interleukin 2, thalidomide) within 1 week before
the first dose of study drug. Bevacizumab within 6 weeks before the first dose of
study drug

2. Pregnant or lactating females

3. Any acute viral, bacterial, or fungal infection that requires parenteral therapy
within 14 days prior to study treatment

4. Known severe hypersensitivity to paclitaxel

5. Severe toxicity with previous taxane treatment

6. Patients being treated with P450 CYP 3A4 or CYP 2C8 enzyme-inducing anti-convulsant
drugs within 14 days prior to treatment with study drug

7. Patients with inadequate hematological, liver, and renal function

8. Known or suspected acute or chronic active Hepatitis B, or Hepatitis C or HIV/AIDS

9. Patients with unstable or uncompensated respiratory, cardiac, hepatic or renal disease
or any other organ system dysfunction, medical condition, or laboratory abnormality
which, in the opinion of the investigator, would either comprise the patient's safety
or interfere with the evaluation of the test material

10. Evidence of persistent Grade 2 or greater neurotoxicity